668 results about "Clinical psychology" patented technology

The information management system disclosed enables caregivers to make better decisions, faster, using aggregated genetic and phenotypic data. The system enables the integration, validation and analysis of genetic, phenotypic and clinical data from multiple subjects who may be at distributed facilities. A standardized data model stores a range of patient data in standardized data classes that encompass patient profile information, patient symptomatic information, patient treatment information, and patient diagnostic information including genetic information. Data from other systems is converted into the format of the standardized data classes using a data parser, or cartridge, specifically tailored to the source system. Relationships exist between standardized data classes that are based on expert rules and statistical models. The relationships are used both to validate new data, and to predict phenotypic outcomes based on available data. The prediction may relate to a clinical outcome in response to a proposed intervention by a caregiver. The statistical models may be inhaled into the system from electronic publications that define statistical models and methods for training those models, according to a standardized template. Methods are described for selecting, creating and training the statistical models to operate on genetic, phenotypic and clinical data, in particular for underdetermined data sets that are typical of genetic information. The disclosure also describes how security of the data is maintained by means of a robust security architecture, and robust user authentication such as biometric authentication, combined with application-level and data-level access privileges.

A method and system for utilizing neurophysiologic information obtained by techniques such as quantitative electroencephalography (QEEG), electrode recordings, MRI in appropriately matching patients with therapeutic entities is disclosed. The present invention enables utilization of neurophysiologic information, notwithstanding its weak correlation with extant diagnostic schemes for mental disorders, for safer and expeditious treatment for mental disorders, discovering new applications for therapeutic entities, improved testing of candidate therapeutic entities, inferring the presence or absence of a desirable response to a treatment, and deducing the mode of action of one or more therapeutic entities. In particular, methods for effectively comparing neurophysiologic information relative to a reference set are disclosed along with database-based tools for deducing therapeutic entity actions on particular patients such that these tools are readily accessible to remote users.

The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.

The disclosed invention primarily relates to methods for assisting and motivating persons with respect to various exercise and rehabilitation regimens they might undertake, mentally as well as physically. The invention also has potential application to for diagnosis and/or treatment of certain mental and physical disorders, and in other situations where a form of companionship may be provided the user. In addition the invention herein provides an enjoyable means of social interaction with others providing further motivation for physical and mental activity represented.

For Parkinson's patients to function at their best, their medications need to be optimally adjusted to the diurnal variation of symptoms. For this to occur, it is important for the managing clinician to have an accurate picture of how the patient's bradykinesia/hypokinesia and dyskinesia and the patient's perception of movement state fluctuate throughout the normal daily activities. The present invention uses wearable accelerometers coupled with computer implemented learning and statistical analysis techniques in order to classify the movement states of Parkinson's patients and to provide a timeline of how the patients fluctuate throughout the day.

The present invention relates to methods of assessing disease susceptibility associated with dietary and lifestyle risk factors. The invention provides for analysis of alleles at loci of genes associated with lifestyle risk factors, and the disease susceptibility profile of an individual is determined by reference to datasets which further match the risk factor with lifestyle recommendations in order to produce a personalized lifestyle advice plan.

Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.

Method and system for receiving one or more dentition conditions of a patient, associating a first set of one or more treatment goals based on the one or more dentition conditions, generating a case difficulty assessment based on the one or more treatment goals, detecting a modification to the case difficulty assessment, retrieving a second set of one or more treatment goals associated with the modified case difficulty assessment, and displaying the second set of one or more treatment goals are provided.

A computer assisted method is provided for diagnosing the in condition of a subject associated with particular activation in one or more regions of interest, the method comprising: having the subject perform a behavior or have a perception adapted to selectively activate one or more regions of interest associated with the condition; measuring activity of the one or more regions of interest as the behavior is performed or the subject has the perception; diagnosing the condition associated with the one or more regions of interest based on the activity in response to the behavior or perception; performing an intervention; and repeating this process one or more times including repeating said behavior, said measuring of activity and said diagnosis at a later time; and observing changes between measurements that are associated with said intervention.

A method and apparatus for evaluating motivational and emotional circuitry in the brain during paradigms focused on specific motivational functions, to directly determine which components and how much the motivational and emotional brain circuitry responds. This circuitry response answers questions focused on normal and abnormal behavior, along with questions regarding the normal and abnormal function of the circuitry. The results of interrogating the motivational and emotional circuitry can be used for objectively measuring, in individual humans or animals, their preferences or responses to motivationally salient stimuli including but not limited to stimuli which are internal or external, conscious or non-conscious, pharmacological or non-pharmacological therapies, diseased based processes or not, financial or non-financial, etc. This method and apparatus for measuring brain activity during motivational and emotional functions can further be used to predict individual choices, preferences and planned behaviors, plus interpret internal experiences without recourse to the subjects participation or their voluntary description of these choices, preferences, planned behaviors, or internal experiences.

Prediction markets are used to determine the probability of an experimental therapeutic, diagnostic, or prophylactic candidate meeting clinical trial and post-trial goals, such as clinical trial endpoints and timelines. The prediction market processes buy and sell orders from market participants, while adjusting the prices of the securities according to the orders. The securities have specific meanings which correspond to goals in clinical trials or other outcomes in clinical candidate development. The price of a security determined by the market corresponds to the probability of the corresponding goal or outcome. The participants are selected for their expert knowledge of specific factors related to candidate development. Using appropriately selected securities and participants, the prediction market may be used to generate probabilities of success useful for long-range planning and valuation, determining production timelines and volumes, management of candidates in a development portfolio, and clinical management of patients by physicians.

The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.

Automated behavioral methods and systems for treating Insomnia that use passive means for determining wake/sleep states.

A computer-implemented method is provided for analyzing patient risk and determining an individual therapeutic treatment plan for a cancer patient. The method includes entering patient medical information into a risk assessment tool; identifying any obtaining missing or out-of-date patient information; initializing the risk assessment tool based on the patient's demographics and cancer characteristics and determining a default treatment plan for the patient; modifying the default treatment plan by observing the modification of a risk score for the patient; and confirming a treatment order for the patient based on a balancing of the risk and treatment plan factors.

The present invention relates to a mental balance or imbalance estimation system (100) and method for estimating a level of mental balance or imbalance of a user (1). The system comprises a skin conductance sensor (20) for sensing the skin conductance of the user (1), the skin conductance over time forming a skin conductance trace (22). The system further comprises a processing unit (10) for receiving and processing the skin conductance trace (22), the processing unit configured to determine at least one stimulus response (24) in the skin conductance trace (22), to determine an estimated cortisol level trace (28) of the user (1) based on the determined at least one stimulus response (24), and to determine the estimated level of mental balance or imbalance of the user (1) based on the estimated cortisol level trace (28).

A system and method for monitoring a user's mental health tor and collect data concerning. The user's use of electronic devices is tracked, such as usage of his mobile phone, tablet and his web activity. The invention “learns” each patient's unique behavioral patterns to be used as a “base line” representing the steady state (chronic phase) of the patient. The algorithmic processing unit detects any irregularities in a patient's behavioral patterns and produces a deterioration prediction. If it is determined that a threshold is exceeded, an alert is sent to a health professional.

A method and apparatus for monitoring medication adherence. The method includes the steps of determining a present adherence state of a patient, receiving video analysis information reporting on a medication administration session, and determining a next adherence state of a patient based upon the present adherence state of the patient and the video analysis information.

The invention discloses the transgenic animal model for pathological anxiety, the method to generate this model, the method to test drugs and drug candidates for the treatment of pathological anxiety and the method to use Wfs1 as target for screening of new anxiolytic drugs to treat pathological anxiety. This animal model is useful to test potential drug candidates for the treatment of diseases caused by pathological anxiety and to screen therapeutic compounds for the psychiatric disorders caused by reduces stress-tolerance and deficiency in adaptation to environmental challenges.

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders. In one aspect, a method for determining the efficacy of secretin, other neuropeptides, peptides, or digestive enzymes for the treatment of an individual diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a sample of feces from an individual, determining a quantitative level of chymotrypsin present in the sample, and correlating the quantitative level of chymotrypsin determined to be present in the sample with the PDD to determine the efficacy of treating the individual with secretin, other neuropeptides, peptides, or digestive enzyme administration. In another aspect, a therapeutic method for treating an individual diagnosed with a PDD pervasive developmental disorder comprises determining the efficacy of secretin, other neuropeptides, peptides, and digestive enzyme administration for the treatment of the individual based on a measure of the individual's chymotrypsin level, and administering secretin, other neuropeptides, peptides, or digestive enzymes to the individual based on the determination of the measure of the individual's chymotrypsin level.

The invention relates to compositions for supporting healthy memory and optimizing mental energy and methods for improving, preventing, and treating mental disorders or deterioration. The compositions of the invention can be formulated as nutritional or dietary supplements.

The present invention provides a method, apparatus, and computer instructions for improved control of clinical trials. In a preferred embodiment, after a clinical trial is initiated, data is regularly cleaned and processed to statistically analyze the data. The outcome includes a predictive measure of the timing and level by which the study will achieve one or more statistically significant levels, allowing mid-course modifications to the study (e.g., in population size, termination, etc.). Modification can be planned as part of the initial protocol, using thresholds or other appropriate criteria relating to the statistical outcome, making possible pre-approved protocol changes based on the statistical findings. This process has significant implications for the management of clinical studies, including ensuring the minimum possible time and number of patients are used in clinical studies to either prove (or disprove) the clinical efficacy of drugs or treatments.

The present invention relates to compositions and methods for treating depression. The compositions and methods comprise the use of anti-inflammatory compounds alone or in combination with antidepressant compounds to down regulate HPA activation through the targeting of peripheral (non-CNS) cytokines.